Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
October 02, 2024 16:28 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
September 09, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) --...
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
August 12, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
Xenon Reports Q2 2024 Financial Results and Business Update
August 08, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates...
Xenon to Report Q2 2024 Financial Results on August 8, 2024
August 01, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and...
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
May 28, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 08, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...